Raviglione MC, Snider DE, Kochi A: Global epidemiology of tuberculosis. JAMA273: 220-226, 1995
2.
WHO. The threat of tuberculosis. 1996
3.
CDC: Tuberculosis Morbidity United States, 1995. MMWR. 45(18):365-370, 1996
4.
CDC: Tuberculosis among foreign-born persons who had recently arrived in the United States Hawaii, 1992-1993, and Los Angeles County, 1993. MMWR44(38):703-707, 1995
5.
CDC: Characteristics of Foreign-Born Hispanic Patients with Tuberculosis—Eight U.S. Counties Bordering Mexico, 1995. MMWR45(47):1032-36, 1996
6.
CDC: Estimates of future global tuberculosis morbidity and mortality. MMWR42:961-964, 1993
7.
CDC: 1993 revised certification system for HIV infection and expanded surveillance case defmition for AIDS among adolescents and adults . MMWR. 41(RR-17):1-19, 1992
8.
Fischl MA, Daikos GL, Uttamchandani RB, et al: Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Ann. Inter. Med.117:184-89, 1992
9.
CDC: Revision of the CDC surveillance case definitions for acquired immunodeficiency syndrome. MMWR. 36(suppl 1-5):15-155, 1987
10.
American Thoracic Society/Centers for Disease Control. Joint statement: control of tuberculosis in the United States: Am. Rev. Respir. Dis.146:1623-33, 1992
11.
Brudney K, Dobkin J: Resurgent tuberculosis in New York City. Am. Rev. Respir. Dis.144: 745-9, 1991
12.
Haas DW and Des Prez RM: Mycobacterium tuberculosis, In Mandell GL, Bennett JE, and Dolin R (eds). Principles and practice of infectious diseases, 4th ed., New York, NY, Churchill Livingston, 1995, pp 2213-43
13.
Peloquin CA, Berning SE: Infection caused by Mycobacterium Tuberculosis . Ann. Pharmacother. 28:72-84, 1994
14.
Daniel TM: Tuberculosis In: Isselbacher KJ, E Braunwald, JD Wilson, et al., eds. Harrison's principles of internal medicine. New York, McGraw-Hill, Inc. pp 710-18, 1994
Goble M, Iseman MD, Madsen LA, et al.: Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N. Engl. J. Med. 328:527-32, 1993
22.
Koo D, Royce S, Rutherford GW: Drug-resistant mycobacterium tuberculosis in California, 1991-1992. Western J. Med. 163(5): 441-5, 1995
23.
CDC: Initial therapy for tuberculosis in the era of multidrug resistance. MMWR. 42(RR-7): 1-8, 1993
24.
American Thoracic Society: Treatment of tuberculosis and tuberculosis infection in adults and children. Am. Rev. Respir. Dis.134: 355-63, 1986
25.
Kopanoff DE, Snider DE, Jr, Caras GJ: Isoniazid-related hepatitis: a U.S. public health service cooperative surveillance study. Am. Rev. Resp. Dis.117:991-1001, 1978
26.
CDC: The use of preventive therapy for tuberculous infection in the United States: Recommendations of the Advisory Committee for the Elimination of TuberculosisMMWR. 39(RR-8):9-12, 1990
27.
Mandell GL and Sande MA: Drugs used in the chemotherapy of tuberculosis and leprosy. In Goodman-Gilman A, Rall TW, Nies AS, Taylor P (eds.), The pharmacological basis of therapeutics, 8th ed. Pergamon Press, New York, New York, 1990 , p. 1146-59
28.
Derby LE, Gutthann SP, Jick H, et al: Liver disorders in patients receiving chlorpromazine or isoniazid . Pharmacotherapy. 13: 353-58, 1993
29.
Bishai WR, Graham NMH, Harrington S, et al: Brief report: rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis. N. Engl. J. Med.334:1573-76, 1996
30.
Grange JM, Winstanley PA, Davies PD: Clinically significant drug interactions with antituberculosis agents. Drug Safety. 11(4):242-51, 1994
31.
Sun E, Heath-Chiozzi M, Cameron DW, et. al: Concurrent ritonavir and rifabutin increase risk of rifabutin-associated adverse event [Abstract no. B.171]. Presented at XI International Conference on AIDSVancouver, July 8, 1996.
32.
CDC: Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR. 45(42):921-25, 1996
33.
Bartlett JG: Protease inhibitors for HIV infection. Ann. Int. Med. 124;1086-8, 1996
34.
McGregor M, Olliaro P, Wolmarans L, et al: Efficacy and safety of rifabutin in patients with newly-diagnosed pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. (in press)
35.
Schwander S, Rusch-Gerdes S, Mateega A, et al: A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. Tubercle Lung Dis.76:210-8, 1995
36.
Blaschke TF and Skinner MH: The clinical pharmacokinetics of rifabutin . Clin. Infect. Dis.22(suppl 1):S15-S22, 1996
37.
Girling DJ: Adverse effects of antituberculosis drugs. Drugs. 23:56, 1982
Peloquin CA: Pharmacology of the antimycobacterial drugs. Med. Clin. North Am.77(6):1253-62, 1993
40.
Rastogi N and Goh KS: In Vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin. Antimic. Agents Chemother.35(9):1933-1936, 1991
41.
Chen CH, Shih JF, Lindholm-levy PJ, Heifets LB: Minimal inhibitory concentrations of rifabutin, ciprofloxacin, and ofloxacin against Mycobacterium tuberculosis isolated before treatment of patients in Taiwan. Am Rev Respir Dis140:987-989, 1989
42.
Fenlon CH, Cynamon MH: In vitro susceptibility of mycobacteria to ciprofloxacin. J. Antimicrob. Chemother.16:575-80, 1986
43.
Piersimoni C, Morbiducci V, Bomigia S, DeSio G, et al.: In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis. Am. Rev. of Resp. Dis.146(6):1445-7, 1992
44.
Sullivan EA, Kreiswirth BN, Palumbo L, et al.: Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet.345(8958): 1148-50, 1995
45.
Peloquin CA, James GT, McCarthy EA, et al: Pharmacokinetics of ethionamide suppositories. Pharmacotherapy . 11:359, 1991
46.
Peloquin CA, Henshaw TL, Huitt GA, et al.: Pharmacokinetic evaluation of para-aminosalicylic acid granules. Pharmacotherapy. 14: 40-46, 1994
47.
Sorg TB and Cynamon M: Comparison of four beta-lactamase inhibitors in combination with ampicillin against Mycobacterium tuberculosis. J. Antimicrob. Chemother.19:59-64, 1987
48.
Watt B, Edwards J, Rayner A, Grindey A, and Harris G : In vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule. Tubercule Lung Dis.73:134-36, 1992
49.
Zhang Y, Steingrube V, Wallace R: Beta-lactamase inhibitors and the inducibility of the beta-lactamase of Mycobacterium tuberculosis. Am. Rev. Respir. Dis.145:657-60, 1992
50.
Chambers HF, Moreau D, Yajko D, et al.: Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis ? Antimicrob. Agents Chemother.39(12):2620-24, 1995
51.
Martos A, Podzamczer D, Martinez-Lacasa J, et al.: Steroids do not enhance the risk of developing tuberculosis or other AIDS-related diseases in HIV-infected patients treated for Pneumocystis carinii pneumonia. AIDS. 9:1037-41, 1995
52.
Senderovitz T, Viskum K: Corticosteroids and tuberculosis. Resp. Med.88:561-65, 1994
53.
Alzeer AH, FitzGerald JM: Corticosteroids and tuberculosis: risks and use as adjunct therapy. Tubercle and Lung Disease. 74:6-11, 1993
54.
Vallejo JG, Ong LT, Starke JR: Clinical features, diagnosis, and treatment of tuberculosis in infants. Pediatrics94(1):1-7, 1994
55.
Starke JR, Taylor-Watts KT: Tuberculosis in the pediatric population of Houston, Texas. Pediatrics. 84:28-35, 1989
56.
Weis SE, Slocum PC, Flais FX, et al: The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. NEJM330(17):1179-1183, 1994
57.
China Tuberculosis Control Collaboration: Results of directly observed short-course chemotherapy in 112 842 Chinese patients with smear-positive tuberculosis. Lancet. 347:358-62, 1996
58.
Berning SE, Madsen L, Iseman MD, Peloquin CA: Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. Am J. Respir. Crit. Care. Med.151:2006-9, 1995
59.
Kennedy N, Berger L, Curram J, et al.: Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin. Infect. Dis.22: 827-33, 1996
